These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6149502)

  • 1. Presynaptic dopaminergic agonists modify brain glucose metabolism in a way similar to the neuroleptics.
    Palacios JM; Wiederhold KH
    Neurosci Lett; 1984 Sep; 50(1-3):223-9. PubMed ID: 6149502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE; Haubrich DR; Williams M
    Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
    Martin GE; Williams M; Haubrich DR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of apomorphine, TL-99 and 3-PPP on yawning in rats.
    Mogilnicka E; Boissard CG; Delini-Stula A
    Neuropharmacology; 1984 Jan; 23(1):19-22. PubMed ID: 6144063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different actions of TL-99 and 3-PPP in producing contraversive turning in the 6-OHDA-lesioned rat.
    Martin GE; Jones JH; Bendesky RJ
    Eur J Pharmacol; 1983 Sep; 92(3-4):275-8. PubMed ID: 6138266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes.
    Williams M; Totaro JA
    Eur J Pharmacol; 1982 Dec; 86(1):35-42. PubMed ID: 7160432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avoidance and ICSS behavioral models dissociate TL-99 and 3-PPP from dopamine receptor antagonists.
    Fenton HM; Hall NR; Gerhardt S; Noreika L; Neale R; Liebman JM
    Eur J Pharmacol; 1983 Aug; 91(4):421-30. PubMed ID: 6617749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of two dopamine agonists, TL-99 and 3-PPP, on prolactin secretion in the rat.
    Gudelsky GA; Passaro E; Meltzer HY
    Eur J Pharmacol; 1983 Jun; 90(4):423-5. PubMed ID: 6884430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of the putative dopamine autoreceptor agonists, 3-PPP and TL-99, with the dopamine-sensitive adenylate cyclase of carp retina.
    Watling KJ; Williams M
    Eur J Pharmacol; 1982 Feb; 77(4):321-6. PubMed ID: 6277674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 receptor agents, but not dopamine D1, modify brain glucose metabolism.
    Palacios JM; Wiederhold KH
    Brain Res; 1985 Feb; 327(1-2):390-4. PubMed ID: 3157422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yawning produced by dopamine agonists in rhesus monkeys.
    Code RA; Tang AH
    Eur J Pharmacol; 1991 Aug; 201(2-3):235-8. PubMed ID: 1686760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.
    Van der Weide J; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1986 Jun; 125(2):273-82. PubMed ID: 3743637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of putative dopamine receptor agonists, TL-99, 3-PPP and RDS-127 on substantia nigra neurons.
    Pinnock RD
    Brain Res; 1984 Jan; 292(1):190-3. PubMed ID: 6697209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
    Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
    Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postsynaptic dopamine agonist properties of TL-99 are revealed by yohimbine co-treatment.
    Pastor G; Fallon S; Welch JJ; Liebman JM
    Eur J Pharmacol; 1983 Mar; 87(4):459-64. PubMed ID: 6303801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do neuroleptics prevent the penetration of dopamine agonists into the brain?
    Westerink BH; Horn AS
    Eur J Pharmacol; 1979 Sep; 58(1):39-48. PubMed ID: 40803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic effects of some dopamine agonists on striatal acetylcholine concentrations.
    Waldmeier PC
    Eur J Pharmacol; 1983 May; 90(1):115-20. PubMed ID: 6873173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.
    Kreiss DS; Bergstrom DA; Gonzalez AM; Huang KX; Sibley DR; Walters JR
    Eur J Pharmacol; 1995 Apr; 277(2-3):209-14. PubMed ID: 7493610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The search for selective dopaminergic autoreceptor agonists.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A; Nilsson JL
    J Neural Transm Suppl; 1983; 18():131-7. PubMed ID: 6576112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.